Global Enteric-coated Tablets Market Size By Type (Aspirin, Serrapeptase), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Enteric-coated Tablets Market was valued at USD 4.7 billion in 2023 and is projected to reach USD 7.8 billion by 2031, growing at a CAGR of 6.5% during the forecast period of 2023–2031. Enteric-coated tablets are pharmaceutical formulations designed to resist disintegration in the stomach, ensuring drug release in the intestinal tract. Their market growth is driven by increasing cases of gastrointestinal disorders, rising preference for targeted drug delivery systems, and heightened awareness about drug absorption efficiency and patient compliance. Innovations in coating technologies and a growing geriatric population are further accelerating demand.

Drivers:

1. Rising Prevalence of Gastrointestinal Disorders:

Chronic conditions such as acid reflux, Crohn’s disease, and peptic ulcers necessitate medications that bypass the stomach. Enteric-coated tablets serve this need efficiently, boosting their demand globally.

2. Growing Demand for Targeted Drug Delivery:

Modern therapeutics are increasingly reliant on delivery systems that optimize bioavailability and minimize side effects. Enteric coatings help protect active pharmaceutical ingredients (APIs) from gastric degradation, making them a preferred choice.

3. Increasing Geriatric Population:

Older adults are more likely to require medications that minimize gastrointestinal side effects. The aging global population is thus a significant driver of market growth.

Restraints:

1. High Manufacturing Costs:

The production of enteric-coated tablets involves complex coating processes, specialized equipment, and stringent quality controls, raising the overall cost of production.

2. Regulatory Challenges:

Strict regulations regarding formulation standards, coating materials, and release profiles often delay product launches and increase compliance burdens on manufacturers.

Opportunity:

1. Technological Advancements in Coating Polymers:

Ongoing R&D in coating materials such as methacrylic acid copolymers and cellulose derivatives is improving tablet efficacy and expanding market potential.

2. Expansion in Emerging Markets:

Rapid urbanization, improving healthcare infrastructure, and increasing pharmaceutical consumption in countries like India, China, and Brazil offer substantial growth opportunities.

3. Customized Drug Delivery Solutions:

The rise in personalized medicine is opening avenues for patient-specific enteric-coated formulations, especially for those with unique gastrointestinal conditions or absorption needs.

Market by System Type Insights:

Based on coating polymer type, the Methacrylic Acid Copolymer segment accounted for the largest market share in 2023. These polymers are preferred due to their strong acid resistance and controlled release properties. The Cellulose Acetate Phthalate (CAP) segment is expected to grow rapidly, owing to its effectiveness in protecting drugs against acidic degradation.

Market by End-use Insights:

By end use, Pharmaceutical Companies dominated the market in 2023, contributing over 50% of the revenue. These firms require large-scale, cost-efficient enteric-coated tablet production for chronic disease treatments. Meanwhile, Contract Manufacturing Organizations (CMOs) are expected to witness substantial growth, driven by outsourcing trends among small and mid-sized pharma enterprises.

Market by Regional Insights:

North America held the largest share in 2023, attributed to the region’s high healthcare spending, advanced drug formulation technologies, and rising incidence of gastrointestinal conditions. Asia-Pacific is poised to experience the fastest growth during the forecast period due to increasing healthcare access, growing elderly population, and expansion of domestic pharmaceutical manufacturing in countries like China and India.

Competitive Scenario:

Key players in the Global Enteric-coated Tablets Market include Bayer AG, Pfizer Inc., Abbott Laboratories, AstraZeneca, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Merck & Co., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and Evonik Industries AG. These companies are actively investing in novel formulation techniques, strategic partnerships, and regional expansion.

Recent Developments:

In 2023, Bayer AG introduced a new line of enteric-coated aspirin with improved gastrointestinal tolerability.

Dr. Reddy’s Laboratories launched a generic version of a popular proton pump inhibitor with enhanced enteric coating in India.

In 2024, Evonik expanded its polymer coating plant in Germany to meet rising demand for functional drug coatings.

Scope of Work – Global Enteric-coated Tablets Market

Key Market Developments:

July 2023: Pfizer received FDA approval for a new enteric-coated formulation of an anti-inflammatory drug targeting pediatric Crohn's disease.

March 2024: AstraZeneca partnered with a biotech firm to develop enteric formulations for oral biologics.

January 2025: Evonik Industries announced the release of next-generation coating polymers designed to enhance stability in high-humidity environments.

FAQs:

What is the current market size of the Global Enteric-coated Tablets Market?

The market was valued at USD 4.7 billion in 2023.

What is the major growth driver of the Global Enteric-coated Tablets Market?

The increasing prevalence of gastrointestinal disorders and demand for targeted drug delivery are key growth drivers.

Which is the largest region during the forecast period in the Global Enteric-coated Tablets Market?

North America is the largest region due to its advanced healthcare infrastructure and high pharmaceutical consumption.

Which segment accounted for the largest market share in Global Enteric-coated Tablets Market?

The Methacrylic Acid Copolymer system type segment held the largest share in 2023.

Who are the key market players in the Global Enteric-coated Tablets Market?

Key players include Bayer AG, Pfizer Inc., Abbott Laboratories, AstraZeneca, and Evonik Industries AG.